GLSI — Greenwich Lifesciences Inc
NASDAQ · Healthcare · Biotechnology
$15.65
+$0.64 (+4.25%)
Greenwich Lifesciences Inc (GLSI) is a biotechnology company listed on NASDAQ. It is led by Snehal S. Patel, based in Building 14, Stafford, TX, United States, 77477, with about 4 employees. Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
Net income was -$4.2M. GLSI currently screens at market cap $144.9M.
Use this GLSI page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the GLSI quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the GLSI SEC filings page. Lician reads the product cache first so this HTML stays unique to Greenwich Lifesciences Inc even when a live quote feed is slow.
About Greenwich Lifesciences Inc
Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was incorporated in 2006 and is headquartered in Stafford, Texas.
GLSI Key Statistics
Market Cap
$144.91M
Volume
59,752
Previous Close
$18.59
Day Range
$17.82 – $18.60
EPS
-$1.21
Revenue
$0.00
Net Income
-$15.79M
Gross Profit
$0.00
Free Cash Flow
$0.00
Employees
4
GLSI Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$15.79M | -$8.89M | -$7.83M | -$4.57M |
| EPS (Diluted) | -$1.21 | -$0.69 | -$0.61 | $0.00 |
Total Assets
$4.09M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$4.09M
Operating Cash Flow
-$7.27M
Free Cash Flow
$0.00
Greenwich Lifesciences Inc Company Information
- CEO, CFO & Director
- Snehal S. Patel
- Headquarters
- Building 14, Stafford, TX, United States, 77477
- Website
- greenwichlifesciences.com
- Phone
- 832-819-3232
- IPO / Founded
- 2020-09-25
- Sector
- Healthcare
- Industry
- Biotechnology